Holen Sie sich die Stockscreener-App
5.38
2.54%
-0.14
Handel nachbörslich:
5.38
Schlusskurs vom Vortag:
$5.52
Offen:
$5.46
24-Stunden-Volumen:
244.55K
Relative Volume:
0.98
Marktkapitalisierung:
$279.75M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-76.41M
KGV:
-2.8021
EPS:
-1.92
Netto-Cashflow:
$-64.56M
1W Leistung:
+0.37%
1M Leistung:
-24.01%
6M Leistung:
-50.73%
1J Leistung:
-24.01%
1-Tages-Spanne:
$5.27
$5.62
1-Wochen-Bereich:
$4.93
$5.9199
52-Wochen-Spanne:
$4.84
$12.38
Aura Biosciences Inc Stock (AURA) Company Profile
Firmenname
Aura Biosciences Inc
Sektor
Branche
Telefon
(617)500-8864
Adresse
80 GUEST STREET, BOSTON
Vergleichen Sie AURA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AURA
Aura Biosciences Inc
|
5.38 | 279.75M | 0 | -76.41M | -64.56M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-04-17 | Fortgesetzt | BTIG Research | Buy |
| 2022-07-19 | Eingeleitet | JMP Securities | Mkt Outperform |
Aura Biosciences Inc Aktie (AURA) Neueste Nachrichten
Aura Biosciences, Inc. (NASDAQ:AURA) Position Increased by Geode Capital Management LLC - Defense World
Oncology’s Most Eligible Unpartnered Assets - insights.citeline.com
Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Up 19.3% in March - Defense World
Vanguard Group Inc. Acquires 112,296 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
Aura Biosciences SVP Amy Elazzouzi sells $4,924 in stock By Investing.com - Investing.com Canada
Aura Biosciences SVP sells $4,924 in stock By Investing.com - Investing.com India
Aura Biosciences executive sells $39,319 in stock By Investing.com - Investing.com Canada
Aura Biosciences executive sells $39,319 in stock - Investing.com Australia
Aura Biosciences SVP sells $4,924 in stock - Investing.com
Aura Biosciences SVP Amy Elazzouzi sells $4,924 in stock - Investing.com
Wellington Management Group LLP Has $1.08 Million Position in Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
American Century Companies Inc. Has $392,000 Stake in Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
Q1 EPS Estimate for Aura Biosciences Decreased by Analyst - Defense World
Aura Biosciences, Inc. (NASDAQ:AURA) Receives Consensus Rating of “Buy” from Analysts - Defense World
Aura Biosciences stock hits 52-week low at $5.05 - Investing.com Australia
Aura Biosciences stock hits 52-week low at $5.05 By Investing.com - Investing.com South Africa
Is Aura Biosciences (AURA) The Small Cap Stock with Huge Upside Potential? - Insider Monkey
10 Small Cap Stocks with Huge Upside Potential - Insider Monkey
Aura Biosciences expands board with oncology leader By Investing.com - Investing.com South Africa
Aura Biosciences Appoints Teresa Bitetti To Board - citybiz
Aura Biosciences Announces Appointment Of Teresa Bitetti To Board Of Directors - MarketScreener
Aura Biosciences Expands Board with New Director Appointment - TipRanks
Aura Biosciences expands board with oncology leader - Investing.com
Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors - GlobeNewswire
Aura Biosciences stock hits 52-week low at $5.75 amid market challenges By Investing.com - Investing.com South Africa
Aura Biosciences stock hits 52-week low at $5.75 amid market challenges - Investing.com Australia
Are Investors Keen On Selling Holdings In Aura Biosciences Inc (NASDAQ: AURA)? - stocksregister.com
(AURA) Long Term Investment Analysis - news.stocktradersdaily.com
Q1 Earnings Estimate for AURA Issued By HC Wainwright - Defense World
Aura Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Institutional investors may adopt severe steps after Aura Biosciences, Inc.'s (NASDAQ:AURA) latest 20% drop adds to a year losses - Simply Wall St
Aura Biosciences Inc: Promising Clinical Progress and Financial Stability Justify Buy Rating - TipRanks
What is HC Wainwright’s Forecast for AURA Q3 Earnings? - Defense World
Aura Biosciences Stock (AURA) Continues to Slide Despite Promising Clinical Progress - markets.businessinsider.com
Aura Biosciences price target lowered to $19 from $21 at Citizens JMP - TipRanks
Character Biosciences gains $93m for precision eye disease therapies - Pharmaceutical Technology
Bel-sar shows promising safety, efficacy in NMIBC - Urology Times
Aura Biosciences stock target cut to $19 by JMP Securities - Investing.com UK
Aura Biosciences Reports Progress in Cancer Trials - TipRanks
Aura Biosciences Inc expected to post a loss of 49 cents a shareEarnings Preview - TradingView
Aura Biosciences stock target raised to $25 by H.C. Wainwright - Investing.com UK
Promising Clinical Data and Abscopal Effect Drive Buy Rating for Aura Biosciences Inc. - TipRanks
Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - GlobeNewswire
Aura Biosciences Reports Positive Phase 1 Trial Results in Non-Muscle Invasive Bladder Cancer and Advances Clinical Pipeline - Nasdaq
Aura's Cancer Drug Delivers Complete Responses as $151M Cash Runway Extends to 2026 - Stock Titan
Promising Phase 1 Results for Aura Biosciences’ Bel-sar in Bladder Cancer Boost Buy Rating - TipRanks
Aura reports promising bladder cancer trial results By Investing.com - Investing.com South Africa
Aura Biosciences stock hits 52-week low at $6.58 amid market shifts - Investing.com Australia
Buy Recommendation for Aura Biosciences: Promising Phase 1 Trial Results and Dual Mechanism of Action in Bladder Cancer Treatment - TipRanks
Finanzdaten der Aura Biosciences Inc-Aktie (AURA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.24%
36.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):